Technetium (99mTc) tilmanocept

Technetium (^99mTc) tilmanocept

Clinical data
Trade names	Lymphoseek
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Tilmanocept
Pregnancy category	AU: C
Routes of administration	Intradermal, subcutaneous, intratumor
ATC code	V09IA09 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)& UK: POM (Prescription only) US: ℞-only EU: Rx-only
Pharmacokinetic data
Elimination half-life	1.75 to 3.05 hours at injection site
Identifiers
IUPAC name Dextran 3-[(2-aminoethyl)thio]propyl 17-carboxy-10,13,16-tris(carboxymethyl)-8-oxo-4-thia-7,10,13,16-tetraazaheptadec-1-yl 3-[[2-[[1-imino-2-(D-mannopyranosylthio)ethyl]amino]ethyl]thio]propyl ether technetium-99m complexes
CAS Number	1262984-82-6 Y
UNII	8IHI69PQTC
KEGG	D11543
Chemical and physical data
Formula	(C6H10O5)n(C19H28N4O9S99mTc)3–8(C13H24N2O5S2)12–20(C5H11NS)0–17
Molar mass	15,281–23,454 g/mol

Technetium (^99mTc) tilmanocept, trade name Lymphoseek, is a radiopharmaceutical diagnostic imaging agent used to locate lymph nodes which may be draining from tumors, and assist doctors in locating lymph nodes for removal during surgery.

The most common side effects identified in clinical trials was pain or irritation at the injection site.

It was approved by the U.S. Food and Drug Administration (FDA) in March 2013, for the imaging of lymph nodes.

External links

• "Technetium Tc 99m Tilmanocept". Drug Information Portal. U.S. National Library of Medicine.